|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 653.00 TWD | -1.06% |
|
+3.49% | +38.94% |
| 04-10 | PharmaEssentia to Buy Forus Therapeutics for C$50 Million | MT |
| 04-09 | PharmaEssentia says to buy 100% Forus Therapeutics for C$50 mln | RE |
| Capitalization | 242B 7.71B 6.53B 6.01B 5.69B 10.54B 713B 10.72B 70.37B 27.59B 346B 28.92B 28.32B 1,219B | P/E ratio 2026 * |
32.6x | P/E ratio 2027 * | 17.6x |
|---|---|---|---|---|---|
| Enterprise value | 218B 6.93B 5.87B 5.4B 5.11B 9.47B 641B 9.64B 63.23B 24.79B 311B 25.98B 25.44B 1,095B | EV / Sales 2026 * |
9.41x | EV / Sales 2027 * | 5.97x |
| Free-Float |
74.32% | Yield 2026 * |
0.26% | Yield 2027 * | 0.3% |
| 1 day | -1.06% | ||
| 1 week | +3.49% | ||
| Current month | +8.83% | ||
| 1 month | +0.62% | ||
| 3 months | +11.24% | ||
| 6 months | +26.31% | ||
| Current year | +38.94% |
| 1 week | 639 |  | 670 |
| 1 month | 595 | | 687 |
| Current year | 470 | | 780 |
| 1 year | 428.03 | | 780 |
| 3 years | 246.91 | | 780 |
| 5 years | 62.18 | | 780 |
| 10 years | 48.3 | | 780 |
| Manager | Title | Age | Since |
|---|---|---|---|
Kuo Chung Lin
CEO | Chief Executive Officer | - | 31/12/2002 |
Hsueh Ling Chang
DFI | Director of Finance/CFO | - | 13/10/2015 |
Albert Qin
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Ching Liu Chan
CHM | Chairman | - | 31/08/2003 |
Cheng Ku Huang
BRD | Director/Board Member | - | - |
Chao Ho Chen
BRD | Director/Board Member | - | 29/06/2009 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.06% | +3.49% | +47.89% | +71.92% | 7.76B | |
| +1.01% | +6.09% | +37.14% | +106.68% | 52.04B | |
| -5.93% | -6.40% | +89.82% | +15.84% | 46.83B | |
| +1.18% | -9.47% | +105.81% | +762.57% | 30.82B | |
| +0.78% | +11.89% | +4.75% | -20.62% | 25.82B | |
| -3.93% | +0.51% | +76.83% | -34.82% | 19.66B | |
| +0.78% | +0.08% | +39.68% | -35.96% | 17.31B | |
| +1.34% | +11.44% | +80.41% | +219.92% | 17.54B | |
| +2.99% | +30.24% | +9.11% | +1,501.91% | 18.93B | |
| -0.38% | +7.17% | +79.93% | - | 15.56B | |
| Average | -0.39% | +4.84% | +57.14% | +287.49% | 25.23B | |
| Weighted average by Cap. | -0.74% | +3.26% | +59.14% | +256.88% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 23.14B 736M 623M 574M 543M 1.01B 68.1B 1.02B 6.72B 2.63B 33.01B 2.76B 2.7B 116B | 36.43B 1.16B 982M 903M 855M 1.58B 107B 1.61B 10.58B 4.15B 51.98B 4.35B 4.26B 183B |
| Net income | 7.6B 242M 205M 188M 178M 330M 22.37B 336M 2.21B 865M 10.84B 907M 888M 38.21B | 13.95B 444M 376M 346M 327M 607M 41.06B 617M 4.05B 1.59B 19.91B 1.66B 1.63B 70.16B |
| Net Debt | -24.62B -783M -663M -610M -578M -1.07B -72.45B -1.09B -7.15B -2.8B -35.12B -2.94B -2.88B -124B | -24.86B -791M -670M -616M -583M -1.08B -73.18B -1.1B -7.22B -2.83B -35.47B -2.97B -2.9B -125B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/04/26 | 653.00 NT$ | -1.06% | 1,794,085 |
| 16/04/26 | 660.00 NT$ | +1.54% | 1,342,439 |
| 15/04/26 | 650.00 NT$ | +1.25% | 1,295,665 |
| 14/04/26 | 642.00 NT$ | -0.77% | 1,407,542 |
| 13/04/26 | 647.00 NT$ | +0.15% | 1,053,756 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 6446 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition